Brief: Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition

Sonnet Biotherapeutics Holdings

09/06/2022 12:35

June 9 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM A
PRECLINICAL COMBINATION STUDY OF SON-1010 WITH ANTI-PD1
CHECKPOINT INHIBITION
    * SONNET - TUMOR VOLUME GROWTH INHIBITION IMPROVEMENTS
OBSERVED
WITH THE COMBINATION OF SON-1010 AND A COMMERCIALLY AVAILABLE
ANTI-PD1 ANTIBODY
    * SONNET - COMBINATION OF SON-1010 WITH ANTI-PD1 INCREASED
SURVIVAL RATE

Source text for Eikon:  ID:nACSZXnW0a 
Further company coverage:  SONN.O 

 ((Reuters.Briefs@thomsonreuters.com;))